A Phase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer

• Published in: Clinical cancer research Vol. 14; no. 14; pp. 4484 - 4490
• Main Authors: Chu, Quincy S.C., Cianfrocca, Mary E., Goldstein, Lori J., Gale, Meg, Murray, Nicholas, Loftiss, Jill, Arya, Nikita, Koch, Kevin M., Pandite, Lini, Fleming, Ronald A., Paul, Elaine, Rowinsky, Eric K.
• Format: Journal Article
• Language: English
• Published: United States American Association for Cancer Research 15.07.2008
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Area Under Curve; Breast Neoplasms - drug therapy; dose escalation; Female; Humans; lapatinib; letrozole; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms - drug therapy; Nitriles - administration & dosage; Nitriles - adverse effects; Nitriles - pharmacokinetics; Ovarian Neoplasms - drug therapy; pharmacokinetics; phase I; Quinazolines - administration & dosage; Quinazolines - adverse effects; Quinazolines - pharmacokinetics; Triazoles - administration & dosage; Triazoles - adverse effects; Triazoles - pharmacokinetics

Purpose: The main objectives of this phase I and pharmacokinetic, open-label study were to determine the optimally tolerated regimen (OTR), safety, pharmacokinetics, and clinical activity of lapatinib in combination with letrozole in patients with advanced solid malignancies. Experimental Design: Pa...